Zhaoyan New Drug plans to acquire 100% equity of Weimei Biotechnology for 975 million yuan

Weimei Biology is a laboratory animal breeding and sales seller. Its business scope: Licensed items: laboratory animal operation; laboratory animal production. Recently, Zhaoyan New Drug plans to acquire 100% equity of Weimei Biotechnology for 975 million yuan.

This article is reprinted from: https://www.itjuzi.com/merger/8849
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment